Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration
Academic Article
Publication Date:
2021
abstract:
To report 2-year efficacy and safety outcomes of 2 dosing regimens of abicipar (every 8 weeks and quarterly, after initial doses) compared with monthly ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).
Iris type:
1.1 Articolo in rivista
List of contributors:
Khurana, Rahul N; Kunimoto, Derek; Yoon, Young Hee; Wykoff, Charles C; Chang, Andrew; Maturi, Raj K; Agostini, Hansjürgen; Souied, Eric; Chow, David R; Lotery, Andrew J; Ohji, Masahito; Bandello, Francesco; Belfort, Rubens; Li, Xiao-Yan; Jiao, Jenny; Le, Grace; Kim, Kimmie; Schmidt, Werner; Hashad, Yehia
Published in: